Magna Ease©心包主动脉生物瓣的远期临床与超声心动图结果
该单中心队列纳入2008至2014年连续1016例使用Magna Ease©瓣膜的行外科主动脉瓣置换术患者,前瞻性收集院内数据并系统随访临床与超声心动图。中位随访9.8年,10年总体生存率为56.8±1.8%,10年免于结构性瓣膜衰败率为96.5±0.8%(Kaplan-Meier法)和97.4±0.6%(竞争风险法),作者认为远期结局良好,但需继续随访以进一步支持其在预期寿命>10-12年患者中的应用。
要点
- 10年免于结构性瓣膜衰败率为96.5±0.8%(Kaplan-Meier法)和97.4±0.6%(竞争风险法)。
- 中度和重度患者-人工瓣膜不匹配分别发生于26.8%和5.4%,与远期死亡率无关联(中度P=0.12,重度P=0.70)。
- 10年免于瓣膜相关死亡率为97.8±0.5%,10年免于再干预率为97.8±0.6%。
核心结论
- 在此Magna Ease生物瓣行外科主动脉瓣置换术的随访中,数据表明远期结局良好(不包括30天结局)。
- 需要继续随访以进一步支持其在预期寿命>10-12年患者中的应用。
研究设计与样本
- 单中心连续1016例使用Magna Ease©瓣膜的外科主动脉瓣置换术队列(2008-2014年),为全人群纳入。
- 前瞻性收集院内数据,并进行系统性临床和超声心动图随访。
主要发现
- 外科主动脉瓣置换术时年龄为73.4±9.5岁,钙化性主动脉瓣狭窄为手术指征者占59.6%。
- 974例患者进入随访,末次随访时564例存活(中位随访时间9.8年,最长至13.4年),纽约心脏协会心功能分级I或II级者占92.1%。
- 10年总体生存率为56.8±1.8%。
- 10年免于结构性瓣膜衰败率为96.5±0.8%(Kaplan-Meier法)和97.4±0.6%(竞争风险法),共28例结构性瓣膜衰败事件,发生于6.9±3.3年后。
- 因结构性瓣膜衰败行再干预15例(再次外科主动脉瓣置换术和经导管主动脉瓣植入术),10年免于再干预率为97.8±0.6%。
关键数值与推荐
- 中度和重度患者-人工瓣膜不匹配分别发生于26.8%和5.4%,与远期死亡率无关联(中度P=0.12,重度P=0.70)。
- 10年免于瓣膜相关死亡率为97.8±0.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要继续随访以进一步支持其在预期寿命>10-12年患者中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The population of candidates to surgical aortic valve replacement (SAVR) is evolving. The Perimount Magna Ease© bioprosthesis has been introduced relatively recently in the practice. We aimed at evaluating its long-term results. METHODS: This article describes a single-centre cohort of 1016 consecutive SAVRs with the Magna Ease© valve (2008-2014), consisting of an all-comers population. We performed a prospective collection of in-hospital data, systematic clinical and echocardiographic follow-up. Valve-related events were as follows: structural valve deterioration (SVD; according to modified definition criteria), nonstructural valve dysfunction, patient-prosthesis mismatch (PPM). RESULTS: Age at SAVR was 73.4 ± 9.5 years; calcified aortic stenosis was the indication to surgery in 59.6%. A total of 974 patients entered the follow-up; 564 were alive at the last follow-up (median duration: 9.8 years) (up to 13.4 years). New York Heart Association class was I or II in 92.1%. Overall survival at 10 years was 56.8 ± 1.8%. Freedom from SVD at 10 was 96.5 ± 0.8% (Kaplan-Meier) and 97.4 ± 0.6% (competing risks) (28 SVD events after 6.9 ± 3.3 years). There were 15 reinterventions for SVD (redo-SAVR and Transcatheter Aortic Valve Implantation (TAVI)); 10-year freedom from reintervention was 97.8 ± 0.6%. Moderate and severe PPM occurred in 26.8% and 5.4%, respectively, without association with late mortality (P = 0.12 for moderate and P = 0.70 for severe PPM). Freedom from valve-related mortality was 97.8 ± 0.5% at 10 years. CONCLUSIONS: In this follow-up of the Magna Ease bioprosthesis for SAVR, data indicate good late outcomes (30-day outcomes are excluded). Continued follow-up is required to further support its use in patients with life expectancy >10-12 years.
引用
- Anselmi A, Aymami M, Tomasi J, et al. Late clinical and echocardiographic results with the Magna Ease© pericardial aortic bioprosthesis. Eur J Cardiothorac Surg. 2024. PMID: 38001032. doi:10.1093/ejcts/ezad351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。